6.6.5. treatment selection patient selection. several network meta-analyses published data concluding combination therapy efficient adt alone, none doublet combination therapies convincingly proven superior another [1132-1137]. sr meta-analysis looking association age efficacy combination therapy patients seemed profit combination therapy irrespective age . consequence, patients offered combination treatment unless clear contra-indications present asymptomatic disease short life expectancy (based non-cancer comorbidities). since data mentioned phase iii trials triplet therapies reported, docetaxel sole addition adt longer valid option majority patients androgen receptor pathway inhibitor (arpi) available contra-indications use one. subgroup analysis above-mentioned rcts know probably subgroups (high vs. low volume/risk synchronous vs. metachronous) profit addition arpi adt. therefore, view current data recommendation using adt plus arpi sole additional therapy triplet arpi plus docetaxel. formally question added value adding docetaxel adt plus arpi evaluated, since triplet therapy seems add lot unexpected overlapping toxicities, data discussed patients fit chemotherapy arpi, realising toxicity caused adding chemotherapy. evidence using triplet synchronous disease os benefit peace-1 seemed driven mostly high volume patients time point analysis publication, arasens patients low volume disease. interest srs meta-analysis authors found significant difference os and/or pfs using systemic triplet therapy compared adding arpi alone adt [1135,1139-1141]. contrast one meta-analysis suggested benefit systemic triplet therapy versus adt arpi another meta-analysis showed benefit patients high volume disease . summary, choice likely driven fitness docetaxel, nature disease (low/high volume; synchronous/metachronous), patient preference, specific side effects, availability, logistics cost.